Drug Interaction Report

Consumer information for this interaction is not currently available.

ADJUST DOSE: Coadministration with weak inhibitors of CYP450 3A4 may increase the plasma concentrations of lemborexant, which is primarily metabolized by the isoenzyme. Concomitant use of a weak CYP450 3A4 inhibitor is predicted to increase lemborexant exposure by less than 2-fold. Increased exposure to lemborexant may increase the risk of adverse reactions such as central nervous system (CNS) depression, sleep paralysis, hallucinations, complex sleep behaviors, worsening of depression or suicidal ideation, nightmares, palpitations, or headache.

MANAGEMENT: The lemborexant dose should be limited to 5 mg no more than once per night when coadministered with weak CYP450 3A4 inhibitors.

Do not consume grapefruit, grapefruit juice, or any supplements that contain grapefruit extract during treatment with lemborexant unless directed otherwise by your doctor. Grapefruit juice can increase the blood levels of lemborexant. This may increase the risk of side effects such as central nervous system depression, abnormal sleep behaviors, worsening of depression or suicidal thoughts, changes in heartbeat, or headache. Talk to your doctor if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.